Design Therapeutics
DSGN13.5702.80% ( +0.370 )
Design Therapeutics (DSGN)
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the t...
- Open
- 13.360
- High
- 13.650
- Low
- 13.080
- Prev. Close
- 13.200
- Volume
- 472.06K
- Turnover
- 6.37M
- Avg Price
- 13.492
- Bid/Ask Ratio
- --
- Amplitude
- 4.32%
- 52wk High
- 17.250
- Volume Ratio
- 1.17
- Turnover Ratio
- 1.43%
Design Therapeutics Analyst Rating
View MoreForecast & Rating
Aug 3, 2026Price forecast
$21.0054.75%
Forecast & RatingStrong buy
7analysts
- Strong buy71.43%
- Buy28.57%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · 8 hours ago
RBC Capital Sticks to Their Buy Rating for Design Therapeutics (DSGN)
- Market Beat · 2 days ago, 07:26 AM
Design Therapeutics (NASDAQ:DSGN) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS
- PUBT · 2 days ago, 07:06 AM
Design Therapeutics Q2 FY26 net loss widens to $20.2 million; R&D expenses rise to $16.4 million
- Earnings Watch · 2 days ago, 07:05 AM
Design Therapeutics | 8-K: FY2026 Q2 Revenue: USD 0
- Unusual Whales · 2 days ago, 07:03 AM
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results
- PUBT · Jun 30 at 07:04 AM
Design Therapeutics begins Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1 patients
